A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors ( PIVOT-02 ) (PIVOT-02)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02983045

Recruitment Status : Active, not recruiting

First Posted : December 6, 2016

Last Update Posted : January 5, 2021

Sponsor:

Collaborator:

Bristol-Myers Squibb

Information provided by (Responsible Party):

Nektar Therapeutics

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Estimated Primary Completion Date :	November 2021
Estimated Study Completion Date :	December 2021

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Veatch JR, Singhi N, Jesernig B, Paulson KG, Zalevsky J, Iaccucci E, Tykodi SS, Riddell SR. Mobilization of pre-existing polyclonal T cells specific to neoantigens but not self-antigens during treatment of a patient with melanoma with bempegaldesleukin and nivolumab. J Immunother Cancer. 2020 Dec;8(2). pii: e001591. doi: 10.1136/jitc-2020-001591.

To Top